Pharmacokinetics of teicoplanin during plasma exchange

Alet, Patrice; Lortholary, Olivier; Fauvelle, F.; Tod, Michel; Généreau, T; Louchahi, M; Léon, Anne; Guillevin, Loı̈c; Petitjean, Olivier

doi:10.1111/j.1469-0691.1999.tb00126.x

Cited by 14 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During plasmapheresis, highly protein-bound drugs such as ceftriaxone and teicoplanin can be removed [ 34 , 35 ]. In this context, the time of administration of these drugs is important.…”

Section: Discussionmentioning

confidence: 99%

Clinical pharmacist assessment of drug-related problems among intensive care unit patients in a Turkish university hospital

Albayrak

Başgut

Aygencel

et al. 2022

BMC Health Serv Res

View full text Add to dashboard Cite

Background Critically ill patients treated in the intensive care units (ICUs) often suffer from side effects and drug-related problems (DRPs) that can be life-threatening. A way to prevent DRPs and improve drug safety and efficacy is to include clinical pharmacists in the clinical team. This study aims to evaluate the classification of drug-related problems and the implementation of clinical pharmacy services by a clinical pharmacist in the ICU of a university hospital in Turkey. Methods This study was carried out prospectively between December 2020 and July 2021 in Gazi University Medical Faculty Hospital Internal Diseases ICU. All patients hospitalized in the intensive care unit for more than 24 h were included in the study. During the study, the clinical pharmacist's interventions and other clinical services for patients were recorded. DRPs were classed according to the Pharmaceutical Care Network Europe V.8.02. Results A total of 151 patients were included during the study period corresponding to 2264 patient-days. Patients with DRPs had a longer hospital stay and a higher mortality rate (p < 0.05). 108 patients had at least one DRP and the total number of DRPs was 206. There was an average of 1.36 DRPs per patient, 71.5% of patients experienced DRP and 89.22 DRPs per 1000 patient-days. A total of 35 ADEs were observed in 32 patients. ADE incidence was per 1000 patient-days 15.45. ADEs were caused by nephrotoxicity (48.57%), electrolyte disorders (17.14%), drug-induced thrombocytopenia (17.14%), liver enzyme increase (8.57%) and other causes (8.57%). Drug selection (40.29%) and dose selection (54.36%) constituted most of the causes of DRPs. Dose change was the highest percentage of planned interventions with a rate of 56.79%. Intervention was accepted at a rate of 90.8% and it was fully implemented. Conclusion In this study, the importance of the clinical pharmacist in the determination and analysis of DRPs was emphasized. Clinical pharmacy services like the one described should be implemented widely to increase patient safety.

show abstract

“…During plasmapheresis, highly protein-bound drugs such as ceftriaxone and teicoplanin can be removed [ 34 , 35 ]. In this context, the time of administration of these drugs is important.…”

Section: Discussionmentioning

confidence: 99%

Clinical pharmacist assessment of drug-related problems among intensive care unit patients in a Turkish university hospital

Albayrak

Başgut

Aygencel

et al. 2022

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…Total clearance (CL t ) was calculated as dose/AUC 0-8 .Specific PK parameters were used to evaluate the effect of TPE on CFP/SUL. The amount of drug eliminated during TPE (Q PE ) was calculated as follows: Q PE = V ep × C ep , where C ep is the concentration in the removed volume V ep 12. The fraction eliminated during TPE (fe%) can be estimated by the equation Q PE /dose of CFP/SUL administered 13.…”

mentioning

confidence: 99%

Pharmacokinetics of cefoperazone/sulbactam in critically Ill thrombotic thrombocytopenic purpura patients undergoing therapeutic plasma exchange

Gao

Lin

et al. 2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

What is known and objectives The aim of this study was to investigate the pharmacokinetics (PK) of cefoperazone (CFP) and sulbactam (SUL) in critically ill thrombotic thrombocytopenic purpura (TTP) patients undergoing therapeutic plasma exchange (TPE). Methods Critically ill TTP patients receiving a dose of 3 g CFP/SUL (2.0 g/1.0 g) intravenously every 8 h were included in the study. TPE session began 10 min after the end of CFP/SUL infusion. Serial blood samples were collected at 0, 1, 2, 3, 4, 6 and 8 h at the fourth infusion with TPE and the sixth infusion without TPE. Effluent samples were collected at the effluent port of plasma eliminated at the end of TPE. Concentrations of CFP and SUL in plasma and effluent were measured using LC‐MS/MS. PK parameters were calculated based on two‐compartment open model. Results Five critically ill TTP patients receiving CFP/SUL monotherapy were enrolled. T1/2α of CFP and SUL with TPE was 0.62 and 1.30 h, respectively. For CFP, T1/2β with TPE were significantly higher than those without TPE (5.85 ± 3.16 vs. 4.41 ± 2.74, p = 0.016). Vss with TPE were significantly higher than those without TPE (7.23 ± 0.89 vs. 5.24 ± 0.80 L, p = 0.024). AUC0‐8 with TPE were significantly lower compared with those without TPE (1380.98 ± 411.99 vs. 1581.61 ± 500.22 mg*h/L, p = 0.011). Relatively, CLt with TPE were significantly higher than those without TPE (1.56 ± 0.46 vs. 1.37 ± 0.44 L/h, p = 0.010). For SUL, Vss and CLt were higher significantly with TPE than those without TPE (28.11 ± 8.42 vs. 18.87 ± 6.45 L, p = 0.002; 10.74 ± 2.01 vs. 8.60 ± 2.10 L/h, p = 0.048). Mean QPE of CFP and SUL were 344.42 ± 55.37 and 34.65 ± 10.09 mg, respectively. Mean fe% of CFP and SUL were 17.22 ± 2.77% and 3.46 ± 1.01%, respectively. What is new and conclusion TPE enhances the clearance of CFP and SUL in critically ill TTP patients. CFP is more likely to be removed than SUL due to its a low V and high Pb. TPE is suggested to begin 1–2 h after the end of CFP/SUL infusion. Plasma concentration monitoring is advised when CFP/SUL must be administered during TPE.

show abstract

Medications and therapeutic apheresis procedures: Are we doing our best?

Ibrahim¹,

Balogun

2013

J of Clinical Apheresis

View full text Add to dashboard Cite

Therapeutic apheresis refers to a group of extracorporeal therapies commonly used in the treatment of a variety of neurological, renal, hematological, and other systemic diseases caused by circulating "toxic agents" that cannot be cleared by other means. This article presents an overview of the concepts underlying the effect of therapeutic apheresis procedures on prescription drugs taken by patients and describes key drug-related and procedure-related factors that may impact drug disposition during therapeutic apheresis. Therapeutic apheresis, and specifically therapeutic plasma exchange (TPE), is the process involving the extracorporeal separation of plasma from the cellular components of blood, discarding the plasma and exchanging it with replacement physiologic fluids such as albumin or fresh frozen plasma to maintain oncotic pressure and blood volume, and then returning this and the original cellular components of blood back to the patient's circulatory system (Ibrahim and Balogun, Semin Dial 2012;25:176-189). Over the last 4 decades, modern therapeutic apheresis has been used clinically for the treatment of a host of renal, hematological, and neurological diseases such as Goodpasture's syndrome, thrombotic thrombocytopenic purpura, and myasthenia gravis to name a few (Ibrahim et al., Pharmacotherapy 2007;27:1529-1549). Because of its ability to remove plasma, TPE can extract circulating drugs residing in this compartment, thereby affecting their disposition and potentially their therapeutic action (Ibrahim and Balogun, Semin Dial 2012;25:176-189; Ibrahim et al., Pharmacotherapy 2007;27:1529-1549; Kale-Pradhan and Woo, Pharmacotherapy 1997;17:684-695; Kintzel et al., J Clin Apher 2003;18:194-205). The aim of this article is to shed light on drug-related and TPE-related factors that may influence drug removal by TPE. Emphasis is put on areas needing improvement in the way of assessing drug removal by TPE. In addition, a call for an expanded investigation of TPEs influence on select compounds is enlisted.

show abstract

Pharmacokinetics of teicoplanin during plasma exchange

Cited by 14 publications

References 15 publications

Clinical pharmacist assessment of drug-related problems among intensive care unit patients in a Turkish university hospital

Clinical pharmacist assessment of drug-related problems among intensive care unit patients in a Turkish university hospital

Pharmacokinetics of cefoperazone/sulbactam in critically Ill thrombotic thrombocytopenic purpura patients undergoing therapeutic plasma exchange

Medications and therapeutic apheresis procedures: Are we doing our best?

Contact Info

Product

Resources

About